Navigation Links
Assegai Wins Big Settlement Against ABBOTT's Subsidiary
Date:5/10/2010

BEIJING, May 10 /PRNewswire-Asia/ -- On April 11, 2010, after a nearly two-year trial, the ten arbitration cases with Beijing Un-Assegai Technical & Trade Co. Ltd. (hereinafter referred to as "Assegai"), a leading distributor of clinical diagnostic products in China, as claimant and U.S. Abbott Laboratories (Abbott U.S.; NYSE: ABT) as respondent have been decided by the China International Economic and Trade Arbitration Commission (CIETAC), which has recently rendered the arbitral awards thereof. The advanced arbitral awards made by three different arbitral tribunals held that Abbott U.S. broke and violated the contracts with Assegai and thereby awarded Assegai a nearly one million U.S. dollar settlement.

According to the arbitral awards, Assegai was the largest distributor of Abbott medical diagnostic products in the North China area, on the basis of the cooperation between Assegai and Abbott U.S. that started in 1999 soon after Abbott U.S.'s entrance into the Chinese market. However, in November 2007, in the 9th successive year of this cooperation, Abbott U.S. cut off the supply of reagents to Assegai without any justification, regardless of the fact that Assegai had just purchased some very costly equipment from Abbott U.S.

Mr. Yongfeng Cao, president of Assegai, commented: "We made a notable contribution in helping Abbott's products to become the first-line products in the Chinese market; in return, however, Abbott U.S. took advantage of its market dominance and deprived us of our right to supply reagents to our customers. By doing this, Abbott U.S. violated our right to property ownership and use, which led to losses of roughly 20 million U.S. dollars. Fortunately, we are gratified that the arbitral tribunals have ruled in our favor, which gives us the opportunity to recover all our economic losses. Against the backdrop all other international clinical diagnostic producers' focus on the Chinese market and sincere wishes for long-term cooperation with China, Abbott U.S.'s behavior shocked all key industry players in China. Next, Assegai will continue in our quest through another one hundred arbitration cases or civil actions that have been filed against Abbott U.S. at CIETAC or local Chinese courts, as we seek further compensation for those estimated losses amounting to 20 million U.S. dollars."


'/>"/>
SOURCE Beijing Un-Assegai Technical & Trade Co. Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
2. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
3. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
4. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
5. Faced With Federal Prosecution, MountainView Agrees to Stop Harassment of RNs in Settlement With Labor Board
6. Relators Attorneys Comment On AtriCure/DOJ Proposed Settlement
7. Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit
8. Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By Guidant
9. LifeVantage Announces Settlement of Zrii Litigation
10. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
11. Patheon and JLL Partners Announce Litigation Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... NEW YORK , Dec. 5, 2016 /PRNewswire/ ... of penicillin in 1948, antibiotics have emerged as ... treating several infectious conditions. In addition, antibiotics are ... have undergone surgery, or immunocompromised patients (cancer patients ... both in healthcare and food production, has rapidly ...
(Date:12/5/2016)... 29, 2016 Several leading Alzheimer,s disease experts ... Inc. at 11 a.m. EST on December 6 ... Clinical Trials for Alzheimer,s Disease (CTAD). The program will ... disease and therapeutic targets that address deficient glucose metabolism ... recent failure of another therapy targeting the amyloid hypothesis, ...
(Date:12/5/2016)... Research and Markets has announced the addition of the ... Research, Disease Diagnostics), End User (Academic & Research Institutes, Pharmaceutical & ... offering. ... The western blotting market is expected ... in 2016, growing at a CAGR of 4.9%. ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 06, 2016 , ... The Behavioral Health Center of Excellence ... organization as a top behavioral service provider in the country. The award celebrates ... satisfaction and qualifications, and consumer satisfaction. These areas are measured via a wide-ranging ...
(Date:12/6/2016)... Cary, NC (PRWEB) , ... December 06, 2016 ... ... cancer research charity, is thrilled to formally announce its Not a Moment to ... Moment to Lose will rally supporters dedicated to declaring victory over cancer. The ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... is now offering HIAC particle counting and sizing services for USP 788 and ... instituted the new service as a response to the needs of pharmaceutical and ...
(Date:12/6/2016)... ... 06, 2016 , ... METTLER TOLEDO has launched its online ... white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user ... documents, webinars and videos available online, visit the METTLER TOLEDO Expertise Library ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble ... Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX for ...
Breaking Medicine News(10 mins):